Arrowhead Pharmaceuticals, Inc. (ARWR)
Market Cap | 4.03B |
Revenue (ttm) | 572.98M |
Net Income (ttm) | -148.42M |
Shares Out | 138.26M |
EPS (ttm) | -1.14 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,873,433 |
Open | 29.55 |
Previous Close | 29.42 |
Day's Range | 29.04 - 30.40 |
52-Week Range | 9.57 - 31.13 |
Beta | 1.01 |
Analysts | Strong Buy |
Price Target | 47.75 (+63.92%) |
Earnings Date | Aug 7, 2025 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is... [Read more]
Financial Performance
In 2024, Arrowhead Pharmaceuticals's revenue was $3.55 million, a decrease of -98.52% compared to the previous year's $240.74 million. Losses were -$599.49 million, 192.0% more than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $47.75, which is an increase of 63.92% from the latest price.
News

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District C...

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & P...

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial...

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & P...

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conferen...

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Citi's 2025 Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President C...

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for ...

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
Arrowhead Pharmaceuticals said on Tuesday it will receive up to $2 billion from Novartis for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as Pa...

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead's precl...

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of Ca...

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D....

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is host...

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majori...

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT)...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Co...

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collabor...

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position r...

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discus...

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the...

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Pha...

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Dover Corporation DOV.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company...

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Glo...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Chris...